Virax Biolabs Group Ltd (CIK: 0001885827) EDGAR, Information, Filings... CompaniesBIO.Com

Virax Biolabs Group Ltd

Mailing address
30 BROADWICK STREET, LONDON, X0, W1F 8LX
Phone
44 020 7788 7414
State location
United Kingdom
State of incorporation
N/A
Fiscal year end
N/A
SIC
2835 - (CF Office: Office of Life Sciences) IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Filings
N/A

Virax Biolabs Group Ltd (CIK: 0001885827) is an American company incorporated in the state of United Kingdom. Head office is located at 30 BROADWICK STREET, LONDON, United Kingdom, W1F 8LX. Work in the industry 2835 - (CF Office: Office of Life Sciences) IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES. Virax Biolabs Group Ltd is a public company and trade via Over-The-Counter (OTC).

Old names:

Virax Biolabs (Cayman) Ltd from 2021-27-Dec to 2021-27-Dec

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Virax Biolabs Group Ltd

Filings	Format	Description	Filed/Effective	File/Film Number
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0000950170-25-033079 (34 Act) Size: KB	Mar-05-2025	001-41440 25708876
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0000950170-25-026073 (34 Act) Size: KB	Feb-25-2025	001-41440 25659403
S-8	Document	Initial registration statement for securities to be offered to employees pursuant to employee benefit plans Acc-no: 0000950170-25-011148 (33 Act) Size: KB	Jan-30-2025	333-284607 25574423
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0000950170-24-139294 (34 Act) Size: KB	Dec-23-2024	001-41440 241570220
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0000950170-24-136922 (34 Act) Size: KB	Dec-17-2024	001-41440 241553732
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0000950170-24-134762 (34 Act) Size: KB	Dec-10-2024	001-41440 241537140
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0000950170-24-129224 (34 Act) Size: KB	Nov-20-2024	001-41440 241480301
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001172661-24-005285 (34 Act) Size: KB	Nov-14-2024	005-94426 241463659
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0000950170-24-119254 (34 Act) Size: KB	Oct-31-2024	001-41440 241412541
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0000950170-24-116493 (34 Act) Size: KB	Oct-23-2024	001-41440 241387893
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0000950170-24-110180 (34 Act) Size: KB	Sep-30-2024	001-41440 241336966
424B5	Document	Prospectus filed pursuant to Rule 424(b)(5) Acc-no: 0000950170-24-110179 (33 Act) Size: KB	Sep-30-2024	333-275893 241336959
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0000950170-24-100027 (34 Act) Size: KB	Aug-23-2024	001-41440 241233623
424B5	Document	Prospectus filed pursuant to Rule 424(b)(5) Acc-no: 0000950170-24-100026 (33 Act) Size: KB	Aug-23-2024	333-275893 241233618
20-F	Document	Annual and transition report of foreign private issuers pursuant to sections 13 or 15(d) Acc-no: 0000950170-24-099115 (34 Act) Size: KB	Aug-20-2024	001-41440 241225470
NT 20-F	Document	Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F Acc-no: 0000950170-24-088958 (34 Act) Size: KB	Aug-01-2024	001-41440 241164339
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0000950170-24-071955 (34 Act) Size: KB	Jun-11-2024	001-41440 241036190
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0000950170-24-047931 (34 Act) Size: KB	Apr-25-2024	001-41440 24873074
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0000950170-24-044600 (34 Act) Size: KB	Apr-16-2024	001-41440 24846111
6-K	Document	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0000950170-24-032238 (34 Act) Size: KB	Mar-15-2024	001-41440 24755331

Recent 20 filings. View all Virax Biolabs Group Ltd filings

Overall rating 5.0

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Virax Biolabs Group Ltd overview
Virax Biolabs Group Ltd job
Virax Biolabs Group Ltd stock
Virax Biolabs Group Ltd ownership
Virax Biolabs Group Ltd CEO
Virax Biolabs Group Ltd documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.